Case Report: Intravitreal Conbercept for Treatment of Choroidal Neovascularisation Secondary to Choriodal Osteoma

CURRENT STATUS: POSTED

Min Wu
The 2nd People's Hospital of Yunnan Province
ynwumin@126.com Corresponding Author

DOI: 10.21203/rs.2.155/v1

SUBJECT AREAS
Internal Medicine Specialties

KEYWORDS
Choroidal osteoma, CNV, intravitreal Conbercept
Abstract

Background: Choroidal osteoma is a rare condition. Although anti-VEGF treatment has been reported to be effective in managing choroidal neovascularisation secondary to choroidal osteoma, to the best of our knowledge, this report is the first report of using conbercept in such condition.

Case presentation: This report describes a case of choroidal neovascularisation secondary to choroidal osteoma. A 37-year old female presented with decreased vision and distortion in left eye. Fundus image revealed an orange-yellow lesion with clear boundary in the macular area. Fluorescein angiography indicated choroidal neovascularization (CNV). OCT, B-scan and CT scan showed features of choroidal osteoma. Intravitreal Conbercept was given for four times over a period of 10 months, resulting stability of visual acuity and regression of CNV.

Conclusions: Intravitreal Conbercept is effective in controlling choroidal neovascularisation secondary to choroidal osteoma.

Background
Choroidal osteoma is a rare, benign tumor which appears as well-defined, orange-red or yellowish subretinal mass. It mainly affects young females. Choroidal osteoma could grow slowly with time. More than half of the patients encounter visual loss.[1-3] Over one third of the patients will develop choroidal neovascularisation (CNV).[4] CNV secondary to choroidal osteoma used to be treated using focal laser, transpupillary thermotherapy (TTT),[5] and photodynamic therapy (PDT).[4] In recent years, anti-vascular endothelial growth factor (anti-VEGF) therapy has been reported to treat CNV secondary to choroidal osteoma, including Bevacizumab and Ranibizumab.[7-12]

We reported one case of CNV secondary to choroidal osteoma treated by intravitreal Conbercept injection.

Case Presentation
A healthy 37 years old female presented with decreased vision and distortion in left eye for over a month in the retina clinic of The 2nd People’s Hospital of Yunnan Province, P.R.China. Best corrected visual acuity (BCVA) was 20/20 in the right eye and 20/33 in the left eye. Past systemic and ocular history was negative. Family history was negative. Clinical examination found the right eye was
normal and an orange-yellow lesion with clear boundary in the posterior pole and sub-retinal haemorrhage on the macular in the left eye (Fig 1). Ultrasound B-scan showed a slightly elevated, high acoustic reflective choroidal mass with shadowing behind (Fig 1). Fundus fluorescein angiography (FFA) showed dot-like hyperfluoresence in the choroidal lesion, blocked fluoresceince due to sub-retinal hemorrhage and leakage of choroidal neovascularization (Fig 2). Optical coherence tomography (OCT) indicated sub-retinal fluid, CNV and choroid elevation (Fig 2). CT scan showed a high intensity lesion in the left eye with the size of 0.6×0.3cm (Fig 1). A diagnosis of CNV secondary to choroidal osteoma was made. After written consent was achieved, 0.5mg/0.05ml intravitreal Conbercept (KangHong Tnc, China) injection was given to the left eye. A total of four injections were given during a period of 10 months, at intervals ranging from 1-3 months to treat the sub-retinal fluid. One month follow-up after the first injection, the BCVA was improved to 20/25 in the left eye and kept stable afterwards. OCT scan showed the sub-retinal fluid decreased and CNV shranked with time after injections (Fig 2). FFA indicated the fully regression of CNV at 6 months after presentation (Fig 2). At the last visit, the BCVA was 20/25 in the left eye. The fundus photography showed depigmentation of the choroidal lesion and fully absorption of sub-retinal hemorrhage (Fig 1). OCT scan revealed some sub-retinal fluid (Fig 2). The patient decided not to get further injection due to asymptomatic feeling.

Discussion And Conclusions

Choroidal osteoma is a rare, slow growing benign tumor. It occurs in all races, however the frequency and exact etiology are unclear. It has young women preference and is unilateral in 80% of cases. The visual prognosis could be poor and is related to multiple factors, such as the tumor location, decalcification status, RPE damage, presence of CNV, sub-retinal fluid and sub-retinal hemorrhages.[2,3] Management of CNV secondary to choroidal osteomas is critical to patients' vision. Various attempts to treat CNV secondary to choroidal osteomas have been reported in the literature, including laser photocoagulation (argon laser, TTT and PDT), surgical removal of CNV, and anti-VEGF therapy. The results from laser photocoagulation and surgical removal of CNV were discouraged and have relation to poor visual outcomes.[3,5,6,7] Anti-VEGF therapy has been used as the first-line option in CNV
related pathology, such as age-related macular degeneration, idiopathic CNV, pathological myopia, etc. Bevacizumab and Ranibizumab have been reported to treat CNV associated with choroidal osteoma effectively.[8-14] A recombinant fusion protein-Conbercept is a novel anti-VEGF drug which was invented and widely used in China. Conbercept works as a receptor decoy for all VEGF isoforms and PI GF. It has been proven to be helpful in managing different retinal neovascular diseases.[15-17] Our case is a young female with CNV secondary to unilateral choroidal osteomas. After a total of 4 injections of intravitreal Conbercept over a period of 10 months, the response to treatment is inspiring and leads to subjective and anatomical improvement. BCVA was improved and stabilized to 20/25, the resolving of sub-retinal fluid and regression of CNV was achieved. In conclusion, Intravitreal injection of the new anti-VEGF agent-Conbercept is effective in improving visual outcome and resolving CNV, sub-retinal fluid and hemorrhages associated with choroidal osteoma.

Declarations
Ethic approval and consent to participate
This study adheres to the tenets of the Declaration of Helsinki and was approved by the Ethical Committee of The 2nd People’s Hospital of Yunnan Province, China.

Consent for publication
The patient gave written consent to participate in this study and for publication of the data and the images obtained from the patient.

Availability of data and materials
Not applicable.

Funding
Funding: This study is supported by the Natural Science Foundation of Yunnan Province (NO. 2017FE467(-195)). The examination fee of this patient is partially covered by the funding. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Competing interests
The author has no financial and non-financial competing interests.

Authors’ Contributions

Wu M carried out the case collection and manuscript preparation.

Acknowledgments

Sincerely acknowledgments should be given to HongKun Zhao, Jie Min and Zhi Chao Sheng.

References

Gass JD, Guerry RK, Jack RL, Harris G. Choroidal osteoma. Arch Ophthalmol.1978;96:428-435

Shields CL, Sun H, Demirci H, Shields JA. Factors predictive of tumor growth, tumor decalcification, choroidal neovascularization, and visual outcome in 74 eyes with choroidal osteoma. Arch. Ophthalmol. 2005;123:1658-1666.

Aylward GW, Chang TS, Pautler SE, Gass JD. A long-term follow-up of choroidal osteoma. Arch Ophthalmol. 1998;116:1337-1341.

Alameddine RM, Mansour AM, Kahtani E. Review of choroidal osteomas. Middle East African Journal of Ophthalmology, 2014,21(3):244-250.

Sharma S, Sribhargava N, Shanmugam MP. Choroidal neovascular membrane associated with choroidal osteoma (CO) treated with trans-pupillary thermotherapy. Indian J Ophthalmol. 2004;52:329e330.

Foster BS, Fernandez-Suntay JP, Dryja TP, Jakobiec FA, D’Amico DJ. Surgical removal and histopathologic findings of a subfoveal neovascular membrane associated with choroidal osteoma. Arch. Ophthalmol. 2003;121:273e276.

Jang JH, Kim KH, Lee SJ, Park JM. Photodynamic therapy combined with intravitreal bevacizumab in a patient with choroidal neovascularization secondary to choroidal osteoma. Korean J Ophthalmol KJO. 2012;26:478e480.

Mansour AM, Arevalo JF, Al Kahtani E, et al. Role of intravitreal antivascular endothelial growth factor injections for choroidal neovascularization due to choroidal osteoma. J Ophthalmol. 2014;2014:210458.

Agarwal M, Kantha M, Mayor R, Venkatesh R, Shroff CM. Bilateral choroidal osteoma with choroidal
neovascular membrane treated with bevacizumab in a child. Middle East Afr J Ophthalmol. 2014;21:265-267.

S. Zafar et al. Intravitreal ranibizumab for treatment of choroidal neovascularization secondary to a bilateral choroidal osteoma. American Journal of Ophthalmology Case Reports 4 (2016) 7-10

Papastefanou VP, Pefkianaki M, Al Harby L, Arora AK, Cohen VM, Andrews RM, Sagoo MS. Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma. Eye (Lond). 2016 Jun;30(6):843-9.

Ahmadieh H, Vafi N. Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab(Avastin). Graefe’s Arch. Clin Exp Ophthalmol. 2007;245:1731e1733.

Lekha T, Renuka N, Prasad H. Anti-vascular Endothelial Growth Factors for Choroidal Neovascularization Secondary to Choroidal Osteoma: Long-term Results. Oman J Ophthalmol.2015,Sep-Dec;8(3):185-7.

Behera M, Das MK. A case of choroidal osteoma in a 10-year-old child. Int Med Case Rep J. 2015;8:273e275.

Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, Dong X, Zhang M, Xing Y, Zhu S, Chen X, Shen Y, Huang H, Yu L, Ke Z, Rosenfeld PJ, Kaiser PK, Ying G, Sun X, Xu X; PHOENIX study group. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX study. Am J Ophthalmol. 2018 Aug 24. pii: S0002-9394(18)30478-1.

Yan M, Huang Z, Lian HY, Song YP, Chen X. Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol. 2018 Sep 5.

Bai Y, Nie H, Wei S, Lu X, Ke X, Ouyang X, Feng S. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. Br J Ophthalmol. 2018 Jul 20.

Figures
Figure 1

Fundus image, ultrasound B scan and CT scan. 1A. Fundus image of the right eye at baseline, showing the choroidal lesion and sub-retinal hemorrhage. 1B. Fundus image of the left eye at baseline; 1C. Fundus image of the left eye at one month after the first injection, showing the choroidal lesion and partially absorption of sub-retinal hemorrhage. 1D. Fundus image of the left eye at the last follow-up, showing depigmentation of the choroidal lesion and fully absorption of sub-retinal hemorrhage. 1E. B-scan Ultrasonography of the left eye, showing a highly reflective choroidal lesion in the posterior pole(red arrow). 1F. CT scan showing a high density lesion of 0.6*0.3cm size in the posterior pole of the left eye. </p>
Figure 2

Fundus fluorescein angiography and Optical coherence tomography of the left eye. 3A-3D: Fundus fluorescein angiography of the left eye at baseline, showing blocked fluorescein due to sub-retinal hemorrhage(green arrow) and leakage of chorioidal neovascularization(red arrow); SE-3H: Fundus fluorescein angiography of the left eye at 6 months after presentation, showing absorption of sub-retinal hemorrhage and fully regression of CNV. 3A. 0:20.46; 3B. 0:34.34; 3C. 4:09.98; 3D. 11:15.18; 3E. 0:22.92; 3F. 1:03.90; 3G. 2:30.60; 3H. 8:14.15. OCT A. Right eye is normal at baseline. OCT B. At baseline, OCT image of the left eye, showing an irregular hyper-reflectivity of the lesion(yellow star), CNV(red arrow) and sub-retinal fluid(green arrow). OCT C. OCT image of the left eye at one month after the first injection, showing an irregular hyper-reflectivity of
the lesion (yellow star), shrunken CNV (red arrow) and diminished sub-retinal fluid (green arrow). OCT D. OCT image of the left eye at one month after the third injection, showing an irregular hyper-reflectivity of the lesion (yellow star), shrunken CNV (red arrow) and diminished sub-retinal fluid (green arrow). OCT E. OCT image of the left eye at the last visit, showing an irregular hyper-reflectivity of the lesion (yellow star), diminished sub-retinal fluid (green arrow). There is no evidence of CNV.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
CAREchecklist-Eng-20160131.docx